Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone for Liver Protection in Hepatocellular Carcinoma Patients Receiving SBRT
NCT05901519Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of prednisone in hepatocellular carcinoma (HCC), sponsored by University of Michigan Rogel Cancer Center. Started Feb 2024; status: recruiting.
02
Drugs
prednisone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05901519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901519.